REGENXBIO Inc. (NASDAQ:RGNX) Receives $33.45 Consensus Target Price from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $34.70.

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Morgan Stanley reissued an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Tuesday, February 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th.

Institutional Trading of REGENXBIO

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC raised its position in shares of REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after acquiring an additional 67,948 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after buying an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of REGENXBIO by 602.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 17,533 shares in the last quarter. FMR LLC increased its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp increased its position in shares of REGENXBIO by 13.3% in the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock valued at $1,566,000 after buying an additional 17,563 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Down 0.5 %

NASDAQ RGNX opened at $6.57 on Tuesday. The stock’s 50 day moving average is $7.57 and its two-hundred day moving average is $9.43. The company has a market capitalization of $325.51 million, a price-to-earnings ratio of -1.31 and a beta of 1.29. REGENXBIO has a 1-year low of $6.34 and a 1-year high of $28.80.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.